Crescent Biopharma, Inc.
CBIO
$13.41
$0.322.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.54M | 8.95M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.89M | 21.03M | |||
| Operating Income | -25.89M | -21.03M | |||
| Income Before Tax | -24.61M | -21.79M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.61M | -21.79M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.61M | -21.79M | |||
| EBIT | -25.89M | -21.03M | |||
| EBITDA | -25.86M | -21.03M | |||
| EPS Basic | -1.27 | -4.93 | |||
| Normalized Basic EPS | -0.79 | -3.08 | |||
| EPS Diluted | -1.27 | -4.93 | |||
| Normalized Diluted EPS | -0.79 | -3.08 | |||
| Average Basic Shares Outstanding | 19.43M | 4.42M | |||
| Average Diluted Shares Outstanding | 19.43M | 4.42M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||